Increasing Vegetable Intake Does Not Slow Prostate Cancer
Behavioral intervention had no impact on time to progression among men with early-stage disease.
Prostate Cancer
Prostate Cancer Treatment Side Effects Worse With Prostatectomy
In a study, localized prostate cancer patients reported clinically meaningful differences in urinary, bowel, sexual, and hormonal function by management option up to 5 years of follow-up.
Kegel Exercises After Prostate Surgery Called Into Question
Pelvic physical therapy may be more appropriate than Kegel exercises in managing post-radical prostatectomy pain and stress urinary incontinence, according to a new study.
The FDA Approval Process Needs Refinement, Not a Total Overhaul
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
How Durable Are Responses to Targeted Therapies Across Single-Arm Cancer Trials?
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators.
MRI-Guided Transurethral Ultrasound Ablation: Promising Data in Prostate Cancer
MRI-guided TULSA uses a transurethral catheter to precisely apply ultrasound and MRI-guided thermotherapy to ablate cancerous tissue within the prostate gland.
Reporting Mechanisms for Conflict of Interest Disclosures in Medicine Need Standardization
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system.
Active Surveillance for Low-Risk Prostate Cancer: Can Different Protocols Impact Clinical Outcomes?
Heterogeneity in protocols across centers has contributed to a lack of long-term outcomes for different active surveillance protocols.
New Vaccine Could Delay ADT Use in Stage D0 Prostate Cancer
If the vaccine is shown to work, it may help delay the use of ADT in such patients, Dr Maeng said.
FDA Expands Indication for Xtandi to Treat Metastatic Castration-Sensitive Prostate Cancer
The primary end point was radiographic progression-free survival (rPFS), defined as the time from randomization to radiographic disease progression at any time or death within 24 weeks after drug discontinuation.
Next post in Prostate Cancer
